



INDEX

Sr No.	TITLE	Page No.
1	INTRODUCTION	1
1.1	Outline of the problem	1
1.2	Nanotechnology and tumor targeting	2
1.3	Proposed rationale of Project	4
1.4	Hypothesis	8
1.5	Aims and Objectives	8
1.6	Reference	10
2	LITERATURE REVIEW	15
2.1	Cancer and bone metastasis	15
2.1.1	Participation of Bone Microenvironment in Cancer	15
2.1.2	Vicious cycle between cancer and bone stroma	17
2.1.3	Factors influencing bone metastasis	18
2.1.4	Systematic spread of the tumour cells	19
2.1.5	Colonizing the bone	22
2.1.6	Sheltering inside the bone marrow	24
2.2	Targeting molecule platforms	25
2.2.1	Antibodies or antibody fragments	25
2.2.2	Peptides	26
2.2.3	Small molecule targeting	27
2.2.4	Aptamers	28
2.3	Novel Targets for cancer	29
2.3.1	Vascular endothelial growth factor receptor	29
2.3.2	$\alpha\beta 3$ Integrin	31
2.3.3	Vascular cell adhesion molecule	32
2.3.4	Matrix metalloproteinases	33
2.3.5	Human epidermal receptor	34
2.3.6	Transferrin receptors	34
2.4	Nanoparticle	36
2.4.1	PLGA Nanoparticle	38
2.4.2	PBCA Nanoparticle	42
2.4.2.1	Preparation and Characterization of PEGylated PBCA NPs	45
2.5	Bisphosphonates	47
2.5.1	Bisphosphonates as anticancer	47
2.5.2	Inhibition of tumor cell proliferation and induction of apoptosis in vitro	48
2.5.3	Inhibition of tumor cell adhesion and invasion	49
2.5.4	Effects on the secretion of growth factors and cytokines	50
2.5.5	Inhibition of angiogenesis	51
2.5.6	Inhibition of bone metastases in vivo	51
2.5.7	Evidence of antitumor efficacy in vivo	52

2.5.8	Immunomodulatory effects of bisphosphonates	52
2.6	Docetaxel as anticancer drug	52
2.6.1	Molecular targets of Docetaxel	53
2.6.1.1	An antimicrotubule agent	53
2.6.1.2	Docetaxel influences apoptosis pathways	54
2.6.1.3	Docetaxel inhibits angiogenesis	54
2.7	Combination effect of Zoledronic acid and Docetaxel	55
2.8	Reference	57
3.	ANALYTICAL METHODS	77
3.1	Estimation method for Docetaxel	77
3.1.1	High Performance Liquid Chromatography (HPLC) conditions	77
3.1.2	Preparation of standard stock solutions	77
3.1.3	Preparation of calibration curve	77
3.1.4	Accuracy and Precision	79
3.1.5	Construction of calibration plot in formulation composition	80
3.1.6	Accuracy and precision in formulation	80
3.2	Estimation of IPP and ApppI	81
3.2.1	Cells treatment and sample preparation for LC-MS	81
3.2.2	Ion-pair HPLC	82
3.2.3	Identification of IPP and ApppI using LC-MS	82
3.2.4	Standardization and calibration curve preparation of IPP and ApppI	86
3.2.5	Quantification of the total amounts of IPP and ApppI	86
3.2.6	Stability of IPP and ApppI in sample	90
3.2.7	Linearity, accuracy and precision of IPP, and ApppI	90
3.2.8	Extraction recovery, repeatability and matrix effect	91
3.2.9	Stability	92
3.3	Estimation of coumarin-6	93
3.3.1	Method of estimation	93
3.3.2	Preparation of Calibration Plot in ACN	93
3.3.3	Accuracy and Precision	94
3.4	Estimation of Poloxamer P188	95
3.4.1	Experimental method	95
3.4.2	Preparation of standards and calibration plot	95
3.4.3	Accuracy and Precision	97
3.5	Estimation of PEG	97
3.5.1	Method for PEG estimation	97
3.5.2	Preparation of standards and calibration plot	98
3.5.3	Accuracy and Precision	99
3.6	Estimation of Zoledronic acid	100
3.6.1	Method for Zoledronic acid estimation	100
3.6.2	Preparation of standards and calibration plot	100
3.6.3	Accuracy and Precision	102

3.7	Reference	104
4.	FORMULATION DEVELOPMENT, CHARACTERIZATION AND STABILITY STUDIES	105
4.1	Introduction	107
4.2	PLGA Nanoparticle	107
4.2.1	Materials and Method	107
4.2.2	Stability studies	113
4.2.3	Result and discussion	114
4.2.4	Stability study	132
4.2.5	Conclusion	133
4.3	PBCA Nanoparticle	133
4.3.1	Introduction	133
4.3.2	Material and method	135
4.3.3	Results and Discussion	141
4.3.4	Stability studies	165
4.3.5	Conclusion	166
4.4	Reference	168
5.	IN-VITRO CELL LINE STUDIES	175
5.2	Materials	175
5.3	Cell culture	176
5.4	Opsonization and phagocytosis	176
5.4.1	Cell line protocol for phagocytosis (microphage uptake)	177
5.4.2	Microphage uptake of PLGA NP	177
5.4.3	Microphage uptake of PBCA NP	179
5.5	Cell up take by MCF7 and BO2 cell line	183
5.5.1	Cell line protocol for cell uptake	184
5.5.2	PLGA NP uptake by cancer cell	184
5.5.3	PBCA NP uptake by cancer cell	187
5.6	Cell uptake route characterization	189
5.6.1	Introduction	189
5.6.1.1	Clathrin-dependent Receptor-mediated endocytosis	190
5.6.1.2	Fluid phase endocytosis (FPE)	190
5.6.1.3	Caveolin assisted receptor mediated endocytosis	191
5.6.2	Protocol for NP uptake route characterization	192
5.6.3	Cell uptake route characterization for PLGA NP	192
5.6.4	Cell uptake route characterization for PBCA NP	196
5.6.5	Microscopy for endosomal-lysosomal association	198
5.7	Intracellular residence of NP	198
5.7.1	Protocol for intracellular residence	198
5.7.2	Intracellular residence of PLGA NP with time	200
5.7.3	Intracellular residence of PBCA NP with time	202
5.8	Cytotoxicity by MTT assay	202
5.8.1	Protocol for cytotoxicity assay of formulation using MTT assay	202

5.8.2	Cytotoxicity assay of PLGA NP	203
5.8.3	Cytotoxicity assay of PBCA NP	209
5.9	Cell cycle analysis	216
5.9.1	Protocol of cell cycle analysis	216
5.9.2	Cell cycle analysis of PLGA NPs	217
5.9.3	Cell cycle analysis of PBCA NPs	220
5.10	Apoptosis using annexin V-FITC and PI marker	222
5.10.1	Protocol for apoptosis study using annexin VI-FITC marker	222
5.10.2	Apoptosis evaluation of PLGA NPs	222
5.10.3	Apoptosis evaluation of PBCA NPs	225
5.11	IPP and ApppI measurement	228
5.11.1	Cells treatment and sample preparation for LC-MS	230
5.11.2	Estimation of IPP and ApppI using LC-MS	230
5.11.3	Quantification of the total amounts of IPP and ApppI	231
5.12	Conclusion	237
5.13	Reference	239
6.	IN VIVO PHARMACOKINETIC AND BIODISTRIBUTION STUDIES	243
6.1	Introduction	243
6.1.1	Radio Tagging Chemistry	243
6.1.2	Biodistribution and tumor targeting of Nanoparticles	244
6.2	Radiolabeling of formulations and optimization	244
6.2.1	Materials	244
6.2.2	Radio-tagging and optimization	245
6.3	Biodistribution Studies	247
6.4	Results and Discussion	247
6.4.1	PLGA formulations	251
6.4.2	PBCA formulations	254
6.5	Conclusion	257
6.6	Reference	258
7	SUMMARY AND CONCLUSION	260
7.1	Introduction	260
7.2	Analytical methods	261
7.3	Formulation, development, characterization and stability studies	262
7.4	In vitro cell line studies	266
7.5	In vivo pharmacokinetic and biodistribution studies	269
7.6	Conclusion	271